A Pilot Study of Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 206
- 试验地点
- 1
- 主要终点
- Overall survival (OS)
研究概览
简要总结
The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients. We analyzed clinicopathologic features of advanced OSCC patients who received PD-1 inhibitors in combination with carboplatin and paclitaxel before surgical tumor resection between 2020 and 2022. The Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and pathologic response were used to evaluate the efficacy of the NACI treatment. Adverse events apparently related to NACI treatment were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. Disease-free survival (DFS) and overall survival (OS) were calculated using the Kaplan-Meier survival curves and compared using the log rank test. Additionally, we calculated the area under curve (AUC) to compare the predictive value of PD-L1 expression with baseline serum lipid biomarkers for patient response.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with advanced OSCC who received NACI before surgery
- •Confirmation of primary OSCC by two experienced pathologists;
- •Clinical stage III/ IVA (cT1-2/cN1-2/M0 or cT3-4a/cN0-2/M0) according to the 8th Edition of American Joint Committee on Cancer (AJCC) guideline;
- •An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
- •No prior anti-cancer therapy;
- •Locally resectable advanced tumor evaluated by a head and neck surgeon.
- •Advanced OSCC patients who only received surgery
- •A histopathologic diagnosis of primary OSCC;
- •A clinical stage of III/IVA (AJCC, 8th edition);
- •An ECOG performance status of 0 to 1.
排除标准
- •Patients with advanced OSCC who received NACI before surgery
- •Patients with other pathological types, without NACI or Surgery;
- •Incomplete pre-treatment data;
- •Lost to follow up were excluded from the study.
- •Advanced OSCC patients who only received surgery
- •Patients who had received other therapies targeting the head and neck region before the surgery or those with evidence of recurrence or metastasis, as assessed by physical examination reports or imaging studies before surgery
- •Lost to follow up.
研究组 & 干预措施
neoadjuvant chemoimmunotherapy+surgery
Patients who underwent neoadjuvant chemoimmunotherapy before surgery
干预措施: PD-1 inhibitor+carboplatin+albumin-bound paclitaxel (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: 2 years
The time(years) from day 1 of study treatment until death from any cause.
Disease-free survival （DFS）
时间窗: 2 years
DFS(by months) is defined as the time from treatment until the date of the first relapse (local/regional recurrence or distant metastasis) or death (from any cause) whichever comes firsts and regardless of whether the patient withdraws from treatment or receives another anti-cancer therapy prior to disease DFS is defined as the time from treatment until the date of the first relapse (local/regional recurrence or distant metastasis) or death (from any cause) whichever comes firsts and regardless of whether the patient withdraws from treatment or receives another anti-cancer therapy prior to disease relapse.
次要结局
未报告次要终点